Watch for the final prospectus supplement disclosing offering size, price, and dilution percentage. The lack of disclosed terms suggests uncertainty; pricing at a discount to market could amplify bearish pressure.
Price Chart
Executive Summary
Spyre Therapeutics announced an underwritten public offering of common stock, with an underwriter option for an additional 15% of shares. The offering size and pricing are undisclosed. Proceeds will fund pipeline programs in gastroenterology, rheumatology, and dermatology, including advancing SPY072 into late-stage development for hidradenitis suppurativa. This dilutive event is bearish for existing shareholders given the uncertainty of terms and dilution magnitude.
Key Facts
- Spyre commenced an underwritten public offering of common stock; size and pricing not disclosed.
- Underwriters have a 30-day option to purchase an additional 15% of shares offered.
- Jefferies, TD Cowen, Leerink Partners, and Stifel are joint book-running managers; LifeSci Capital is passive bookrunner.
- Proceeds will fund preclinical studies, clinical trials, manufacturing, Phase 3 readiness, and SPY072 development for hidradenitis suppurativa.
- Registration statement on Form S-3 (File No. 333-297063) became effective June 26, 2026.
Financial Impact
Undisclosed offering size; dilution to existing shareholders is certain but magnitude unknown until pricing.
Risk Factors
- Dilution from new shares issued in the offering.
- Potential discount to market price if offering is priced below current trading levels.
- Execution risk on pipeline programs; proceeds may not be sufficient to reach key milestones.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3374974 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 12, 2026 15d ago | Institutional Cluster | $85.90 | awaiting T+20 | — | $99.04 (+15.30%) |
Oct 9, 2026 18d ago | SC 13D/A | $85.90 | awaiting T+20 | — | $99.04 (+15.30%) |
Oct 7, 2026 20d ago | 8-K | $80.85 | awaiting T+20 | — | $99.04 (−22.50%) |
Oct 6, 2026 21d ago | 424B5 | $80.85 | awaiting T+20 | — | $99.04 (−22.50%) |
Oct 5, 2026 22d ago | Press Release | $80.11 | awaiting T+20 | — | $99.04 (−23.64%) |
Oct 5, 2026 22d ago | 424B5 | $80.11 | awaiting T+20 | — | $99.04 (−23.64%) |
Oct 5, 2026 22d ago | Press Release | $80.11 | awaiting T+20 | — | $99.04 (−23.64%) |
Oct 2, 2026 25d ago | Insider Cluster | $92.72 | awaiting T+20 | — | $99.04 (−6.82%) |
Sep 3, 2026 7w ago | Insider Cluster | $88.98 $92.72 | ▼ −4.20% | ▼ −3.60% | $99.04 (−11.31%) |
Aug 10, 2026 11w ago | Insider Cluster | $102.74 $86.93 | ▲ +15.39% | ▲ +14.33% | $99.04 (+3.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers